4//SEC Filing
Krehlik Carrie 4
Accession 0000899243-22-009249
CIK 0001629137other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 9:02 PM ET
Size
11.5 KB
Accession
0000899243-22-009249
Insider Transaction Report
Form 4
Krehlik Carrie
Chief Human Resources Officer
Transactions
- Award
Restricted Stock Units
2022-03-01+17,668→ 17,668 total→ Common Stock (17,668 underlying) - Award
Restricted Stock Units
2022-03-01+17,668→ 17,668 total→ Common Stock (17,668 underlying) - Award
Stock Option (Right to buy)
2022-03-01+28,628→ 28,628 totalExercise: $29.87Exp: 2032-02-28→ Common Stock (28,628 underlying)
Footnotes (4)
- [F1]Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
- [F2]The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- [F3]The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- [F4]The shares of Common Stock underlying the stock option vest in 16 equal quarterly installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Documents
Issuer
Global Blood Therapeutics, Inc.
CIK 0001629137
Entity typeother
Related Parties
1- filerCIK 0001823899
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 9:02 PM ET
- Size
- 11.5 KB